Pharma Capital

Drug developer Motif Bio's antibiotic successfully completes first phase III trial

The REVIVE-1 global study assessed the drug’s ability to treat patients with acute bacterial skin and skin structure infections
bacteria.jpg
The company are waiting for the results of second trial before filing a new drug application

Motif Bio Plc (LON: MTFB, NASDAQ:MTFB) chief executive Graham Lumsden hailed as a “significant achievement” the successful completion of a phase III clinical trial of its next-generation antibiotic, iclaprim.

The REVIVE-1 global study assessed the drug’s ability to treat patients with acute bacterial skin and skin structure infections (ABSSSI).

WATCH: Motif boss: "All good news" ... 

SIGN-UP: Click to receive the Proactive newsletter

The top-line results revealed it scored well against one of the leading products, vancomycin, on two counts.

Researchers were assessing whether iclaprim was ‘non-inferior’ to vancomycin in the 48 to 72 hours after the start of administration and at the test of cure, a week to a fortnight after patients stop receiving treatment. It also did well in meeting several secondary ‘endpoints’, investors were told.

Kidney disease boost

Data from REVIVE-2, the second phase III trial, which uses an identical protocol but has different trial centres, are expected in the second half of the year.

Motif plans to make a new drug application in the first half of 2018.

It is thought iclaprim could be an important treatment for patients with ABSSSI who may have kidney disease – which is around a quarter of the 3.6mln annually that catch the infection.

"The successful completion of REVIVE-1 is a significant achievement for Motif Bio. I would like to thank the patients and physicians that participated in this important study,” said CEO Lumsden.

Ian_55ae0ddd437b7.jpg
Why Invest In Motif Bio Plc? Read More Here

Register here to be notified of future MTFB Company articles
View full MTFB profile

Motif Bio Plc Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.